Pages that link to "Q56166954"

The following pages link to Pepijn Vemer (Q56166954):

Displaying 14 items.

• Economics of chronic diseases protocol: cost-effectiveness modelling and the future burden of non-communicable disease in Europe (Q33719803) (← links)
• A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children (Q34291104) (← links)
• Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor (Q35178018) (← links)
• Let's get back to work: survival analysis on the return-to-work after depression (Q37261201) (← links)
• The road not taken: transferability issues in multinational trials. (Q38131747) (← links)
• Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. (Q39362544) (← links)
• Higher Adherence During Reimbursement of Pharmacological Smoking Cessation Treatments. (Q41202699) (← links)
• If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands (Q42958013) (← links)
• Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. (Q43267003) (← links)
• Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force (Q44356275) (← links)
• A choice that matters? Smulation study on the impact of direct meta-analysis methods on health economic outcomes. (Q44628538) (← links)
• Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research (Q47192296) (← links)
• Health-related quality of life and productivity losses in patients with depression and anxiety disorders. (Q48080608) (← links)
• Not simply more of the same: distinguishing between patient heterogeneity and parameter uncertainty (Q85302169) (← links)